队列简介：PharmAccess非洲（PASER-M）和亚太地区治疗（TASER-M）监测研究，以评估撒哈拉以南非洲和亚太地区的耐药性——艾滋病毒耐药性。 - Suppr

Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific.

作者信息

Hamers Raph L, Oyomopito Rebecca, Kityo Cissy, Phanuphak Praphan, Siwale Margaret, Sungkanuparph Somnuek, Conradie Francesca, Kumarasamy Nagalingeswaran, Botes Mariette E, Sirisanthana Thira, Abdallah Saade, Li Patrick C K, Ngorima Nicoletta, Kantipong Pacharee, Osibogun Akin, Lee Christopher K C, Stevens Wendy S, Kamarulzaman Adeeba, Derdelinckx Inge, Chen Yi-Ming Arthur, Schuurman Rob, van Vugt Michèle, Rinke de Wit Tobias F

机构信息

PharmAccess Foundation, Amsterdam Institute for Global Health and Development, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

出版信息

Int J Epidemiol. 2012 Feb;41(1):43-54. doi: 10.1093/ije/dyq192. Epub 2010 Nov 10.

DOI:10.1093/ije/dyq192

PMID:21071386

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3304520/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31e8/3304520/1b3a3c497d54/dyq192f1.jpg

相似文献

Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific.

Int J Epidemiol. 2012 Feb;41(1):43-54. doi: 10.1093/ije/dyq192. Epub 2010 Nov 10.

Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study.

Lancet Infect Dis. 2012 Apr;12(4):307-17. doi: 10.1016/S1473-3099(11)70255-9. Epub 2011 Oct 27.

Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.

Clin Infect Dis. 2015 Dec 1;61(11):1749-58. doi: 10.1093/cid/civ656. Epub 2015 Aug 3.

Short-term risk of anaemia following initiation of combination antiretroviral treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pacific, and central and South America.

J Int AIDS Soc. 2012 Jan 30;15(1):5. doi: 10.1186/1758-2652-15-5.

[AIDS treatment in Africa: the risk of antiretroviral resistance].

Ned Tijdschr Geneeskd. 2007 Dec 1;151(48):2666-71.

Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub-Saharan Africa.

J Infect Dis. 2017 May 1;215(9):1362-1365. doi: 10.1093/infdis/jix089.

Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.

J Antimicrob Chemother. 2016 Oct;71(10):2918-27. doi: 10.1093/jac/dkw218. Epub 2016 Jun 23.

Building capacity for the assessment of HIV drug resistance: experiences from the PharmAccess African Studies to Evaluate Resistance network.

Clin Infect Dis. 2012 May;54 Suppl 4:S261-5. doi: 10.1093/cid/cir995.

Early warning indicators for population-based monitoring of HIV drug resistance in 6 African countries.

Clin Infect Dis. 2012 May;54 Suppl 4:S294-9. doi: 10.1093/cid/cir1015.

The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates.

HIV Clin Trials. 2017 Jul;18(4):149-155. doi: 10.1080/15284336.2017.1349028. Epub 2017 Jul 18.

引用本文的文献

The impact of HIV-1 subtypes on virologic and immunologic treatment outcomes at the Lagos University Teaching Hospital: A longitudinal evaluation.

PLoS One. 2020 Aug 25;15(8):e0238027. doi: 10.1371/journal.pone.0238027. eCollection 2020.

Access to HIV Viral Load Testing and Antiretroviral Therapy Switch Practices: A Multicountry Prospective Cohort Study in Sub-Saharan Africa.

AIDS Res Hum Retroviruses. 2020 Nov;36(11):918-926. doi: 10.1089/AID.2020.0049. Epub 2020 Aug 27.

Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.

AIDS Res Ther. 2020 Jan 31;17(1):2. doi: 10.1186/s12981-020-0258-7.

Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure.

AIDS. 2019 Aug 1;33(10):1635-1644. doi: 10.1097/QAD.0000000000002234.

Adherence to antiretroviral therapy for HIV in sub-Saharan Africa and Asia: a comparative analysis of two regional cohorts.

J Int AIDS Soc. 2017 Mar 3;20(1):21218. doi: 10.7448/IAS.20.1.21218.

Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How.

Infect Dis Ther. 2016 Dec;5(4):407-416. doi: 10.1007/s40121-016-0128-8. Epub 2016 Sep 27.

Smoking and projected cardiovascular risk in an HIV-positive Asian regional cohort.

HIV Med. 2016 Aug;17(7):542-9. doi: 10.1111/hiv.12358.

Clinical Evaluation of an Affordable Qualitative Viral Failure Assay for HIV Using Dried Blood Spots in Uganda.

PLoS One. 2016 Jan 29;11(1):e0145110. doi: 10.1371/journal.pone.0145110. eCollection 2016.

Virological outcome among HIV-1 infected patients on first-line antiretroviral treatment in semi-rural HIV clinics in Togo.

AIDS Res Ther. 2015 Nov 27;12:38. doi: 10.1186/s12981-015-0082-7. eCollection 2015.

Risk group characteristics and viral transmission clusters in South-East Asian patients infected with human immunodeficiency virus-1 (HIV-1) circulating recombinant form (CRF) 01_AE and subtype B.

Kaohsiung J Med Sci. 2015 Sep;31(9):445-53. doi: 10.1016/j.kjms.2015.07.002. Epub 2015 Aug 21.

本文引用的文献

HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia.

J Acquir Immune Defic Syndr. 2010 Sep;55(1):95-101. doi: 10.1097/QAI.0b013e3181e544e0.

Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis.

Lancet Infect Dis. 2009 Jul;9(7):409-17. doi: 10.1016/S1473-3099(09)70136-7.

TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories.

J Virol Methods. 2009 Aug;159(2):185-93. doi: 10.1016/j.jviromet.2009.03.016. Epub 2009 Mar 26.

Geographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-naïve subjects screening for two clinical trials in North America and Western Europe.

HIV Clin Trials. 2009 Mar-Apr;10(2):94-103. doi: 10.1310/hct1002-94.

Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence.

AIDS Rev. 2008 Oct-Dec;10(4):212-23.

The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa.

Antivir Ther. 2008;13(5):625-39.

Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared.

PLoS Med. 2008 Jul 8;5(7):e148. doi: 10.1371/journal.pmed.0050148.

The World Health Organization's global strategy for prevention and assessment of HIV drug resistance.

Antivir Ther. 2008;13 Suppl 2:1-13.

World Health Organization/HIVResNet Drug Resistance Laboratory Strategy.

Antivir Ther. 2008;13 Suppl 2:49-57.

World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites.

Antivir Ther. 2008;13 Suppl 2:15-23.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献